Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Maravai LifeSciences stock | $37.09
Learn how to easily invest in Maravai LifeSciences stock.
Maravai LifeSciences is planning an initial public offering (IPO) to raise up to $1.35 billion. The company is most well known for its mRNA and RNA products, which are used in vaccine development. Most notably, its CleanCap approach is being used in several vaccine trials for COVID-19, though it's too soon to tell if any of those particular vaccines will make it to market.
Here's what we know so far about the IPO, including how to buy in when the stock goes public.
How to buy shares in Maravai LifeSciences
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MRVI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Maravai LifeSciences stock price (NASDAQ: MRVI)Use our graph to track the performance of MRVI stocks over time.
Maravai LifeSciences shares at a glance
|Latest market close||$37.09|
|52-week range||$23.62 - $63.55|
|50-day moving average||$50.94|
|200-day moving average||$43.33|
|Wall St. target price||$59.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$4.12|
Buy Maravai LifeSciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Maravai LifeSciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Maravai LifeSciences price performance over time
|1 week (2021-10-08)||-9.29%|
|1 month (2021-09-17)||-19.49%|
|3 months (2021-07-16)||0.79%|
|6 months (2021-04-16)||1.12%|
|1 year (2020-10-13)||N/A|
|2 years (2019-10-13)||N/A|
|3 years (2018-10-13)||N/A|
|5 years (2016-10-13)||N/A|
Is Maravai LifeSciences under- or over-valued?
Valuing Maravai LifeSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Maravai LifeSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Maravai LifeSciences's P/E ratio
Maravai LifeSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Maravai LifeSciences shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Maravai LifeSciences's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Maravai LifeSciences's EBITDA
Maravai LifeSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $350.1 million.
The EBITDA is a measure of a Maravai LifeSciences's overall financial performance and is widely used to measure a its profitability.
To put Maravai LifeSciences's EBITDA into context you can compare it against that of similar companies.
Maravai LifeSciences financials
|Revenue TTM||$552.2 million|
|Operating margin TTM||58.61%|
|Gross profit TTM||$204.4 million|
|Return on assets TTM||7.02%|
|Return on equity TTM||52.65%|
|Market capitalisation||$4.7 billion|
TTM: trailing 12 months
Shorting Maravai LifeSciences shares
There are currently 2.6 million Maravai LifeSciences shares held short by investors – that's known as Maravai LifeSciences's "short interest". This figure is 3.7% up from 2.5 million last month.
There are a few different ways that this level of interest in shorting Maravai LifeSciences shares can be evaluated.
Maravai LifeSciences's "short interest ratio" (SIR)
Maravai LifeSciences's "short interest ratio" (SIR) is the quantity of Maravai LifeSciences shares currently shorted divided by the average quantity of Maravai LifeSciences shares traded daily (recently around 2.0 million). Maravai LifeSciences's SIR currently stands at 1.26. In other words for every 100,000 Maravai LifeSciences shares traded daily on the market, roughly 1260 shares are currently held short.
To gain some more context, you can compare Maravai LifeSciences's short interest ratio against those of similar companies.
However Maravai LifeSciences's short interest can also be evaluated against the total number of Maravai LifeSciences shares, or, against the total number of tradable Maravai LifeSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Maravai LifeSciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Maravai LifeSciences shares in existence, roughly 20 shares are currently held short) or 0.0289% of the tradable shares (for every 100,000 tradable Maravai LifeSciences shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Maravai LifeSciences.
Find out more about how you can short Maravai LifeSciences stock.
Maravai LifeSciences share dividends
We're not expecting Maravai LifeSciences to pay a dividend over the next 12 months.
You may also wish to consider:
- Hercules Capital (HTGC.US) (7.6% forward annual dividend yield)
- Johnson-and-Johnson (JNJ.US) (2.55% forward annual dividend yield)
Maravai LifeSciences overview
Maravai LifeSciences Holdings, Inc. , a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.
Maravai LifeSciences in the news
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 10, 2021
Maravai LifeSciences : To Host Earnings Conference Call on Wednesday, November 10, 2021
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 10, 2021
Frequently asked questionsWhat percentage of Maravai LifeSciences is owned by insiders or institutions?
Currently 0.215% of Maravai LifeSciences shares are held by insiders and 101.911% by institutions. How many people work for Maravai LifeSciences?
Latest data suggests 490 work at Maravai LifeSciences. When does the fiscal year end for Maravai LifeSciences?
Maravai LifeSciences's fiscal year ends in December. Where is Maravai LifeSciences based?
Maravai LifeSciences's address is: 10770 Wateridge Circle, San Diego, CA, United States, 92121 What is Maravai LifeSciences's ISIN number?
Maravai LifeSciences's international securities identification number is: US56600D1072
More guides on Finder
How to buy Aura Biosciences (AURA) stock when it goes public
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
How to buy Claros Mortgage Trust (CMTG) stock when it goes public
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
How to buy Evotec SE (EVO) stock when it goes public
Everything we know about the Evotec SE IPO, plus information on how to buy in.
How to buy Delimobil Holding SA (DMOB) stock when it goes public
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
How to buy Blue Water Vaccines (BWV) stock when it goes public
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
How to buy Sonendo (SONX) stock when it goes public
Everything we know about the Sonendo IPO, plus information on how to buy in.
How to buy FlexEnergy Green Solutions (FLXE) stock when it goes public
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
How to buy Stran & Company (STRN) stock when it goes public
Everything we know about the Stran & Company IPO, plus information on how to buy in.
How to buy Kidpik Corp (PIK) stock when it goes public
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
How to buy Nuvectis Pharma (NVCT) stock when it goes public
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
Ask an Expert